Paliperidona Sandoz (Paliperidone)

Paliperidone, the active ingredient in Paliperidona Sandoz, is an atypical antipsychotic presented as a tablet for oral use. It treats schizophrenia and schizoaffective disorder in adult patients. GNH USA supplies Paliperidona Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Paliperidona Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone is an atypical antipsychotic that modulates dopamine pathways in psychotic disorders.

- Schizophrenia: Reduces positive and negative symptoms and helps maintain long‑term stability. - Schizoaffective disorder: Improves mood and psychotic symptom control. - Maintenance therapy: Prevents relapse after acute stabilization.

Paliperidone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Akathisia: Restlessness and an urge to move. - Weight gain: Increased appetite leading to modest weight increase. - Somnolence: Drowsiness or fatigue. - Dry mouth: Reduced salivation. - Constipation: Slowed gastrointestinal transit. - Elevated prolactin: Menstrual changes or galactorrhea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Potentially life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: Persistent involuntary movements. - Seizures: Increased risk, especially at higher doses. - Orthostatic hypotension: Dizziness on standing. - Cardiac arrhythmias: QT prolongation risk. - Hyperglycaemia: Elevated blood glucose levels.

When prescribing Paliperidone, clinicians should consider several safety aspects.

- Cardiovascular assessment: Evaluate baseline ECG and monitor for QT prolongation. - Metabolic monitoring: Check weight, glucose and lipid profiles regularly. - Prolactin levels: Observe for signs of hyperprolactinemia. - Pregnancy and lactation: Use only if benefits outweigh risks. - Elderly patients: Start low and titrate slowly to reduce fall risk. - Store at ambient temperature: Keep below 25°C, in the original packaging, protected from moisture.

Paliperidone can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors: May increase paliperidone plasma concentrations. - QT‑prolonging agents: Additive risk of cardiac arrhythmias. - CNS depressants: Enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates: May require dose adjustment of the co‑administered drug. - Antihypertensive agents: Potential additive blood‑pressure lowering effect. - Anticholinergic drugs: May worsen dry‑mouth and constipation. - Herbal supplements (e.g., St. John’s wort): May reduce paliperidone levels. - NSAIDs: May increase risk of bleeding when combined with antiplatelet therapy.